Guardant Health announced a partnership with Verana Health, a digital‑health company that curates regulatory‑grade, therapeutic‑specific electronic health record (EHR) data, to combine its clinicogenomic testing data with Verana’s real‑world datasets. The collaboration is designed to accelerate drug development and improve patient care for solid tumors such as lung, breast, and colorectal cancer by linking genomic profiles to real‑world outcomes.
Verana Health, which recently merged with COTA, now has access to more than 95 million patients through over 20,000 contributing clinicians. The company’s curated EHR datasets provide longitudinal, real‑world evidence that can be paired with Guardant’s genomic data to validate biomarkers and refine treatment selection across a broad range of oncology indications.
Guardant’s data moat already includes genomic information from 1 million patients and hundreds of thousands with epigenomic data. By adding Verana’s longitudinal EHR records from academic and community centers, the partnership expands Guardant’s data ecosystem, enabling more comprehensive biomarker discovery and strengthening its competitive advantage against peers such as Invitae, Qiagen, Tempus, Caris Life Sciences, and Foundation Medicine.
The strategic rationale is to create a unified data platform that supports drug developers and biopharmaceutical partners, potentially opening new revenue streams and reinforcing Guardant’s leadership in precision oncology diagnostics. The partnership positions Guardant to offer a more complete view of patient care journeys, which is increasingly valuable for biomarker validation and therapeutic development.
"The partnership will expedite the discovery of new biomarker‑based therapies for patients and make the drug development process more economical," said Craig Eagle, Guardant’s chief medical officer. "Clinicogenomic data empowers research scientists to test hypotheses by studying patient genomic profiles and real‑world outcomes to guide the development of targeted therapies that can be used to personalize treatment for each cancer patient," added Sujay Jadhav, CEO of Verana Health. Helmy Eltoukhy, co‑founder and co‑CEO of Guardant, noted that the company is "uniquely positioned with scaled offerings spanning both therapy selection and monitoring, and the recent launch of Reveal for therapy response monitoring further strengthens our competitive moat." AmirAli Talasaz, co‑founder and co‑CEO, emphasized Guardant’s "data moat" and "flywheel of data," citing genomic data from 1 million patients and "many hundreds of thousands" of patients with full epigenomic data.
Guardant reported total revenue of $982.0 million for the full year 2025, a 33% increase from 2024, and a non‑GAAP gross margin of 66%. In Q4 2025, revenue reached $281.3 million, up 39% year‑over‑year, with a non‑GAAP gross margin of 66%. While the partnership is expected to open new revenue streams, no specific financial impact has been quantified yet.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.